Palantir Technologies (NASDAQ:PLTR) Trading Down 0.1% – Here’s WhyNadra to launch facial recognition system for elderly New initiative aims to streamline identity verification processes and ensure better access to essential services ISLAMABAD: The National Database and Registration Authority (Nadra) has announced the launch of a groundbreaking facial recognition system designed to assist elderly citizens, particularly pensioners, who face difficulties due to faded fingerprints. The new initiative aims to streamline identity verification processes and ensure better access to essential services. In a consultative conference held at Nadra headquarters, officials and representatives from various regulatory bodies convened to discuss advancements in biometric and identity verification systems. The conference served as a platform to address existing challenges and outline modernization efforts. Lt. Gen. Muhammad Munir Afsar, Chairman of Nadra, highlighted the issues faced by senior citizens, especially pensioners, during identity verification due to weakened fingerprints. He emphasized the importance of adopting modern technologies to cater to the needs of this vulnerable group. Starting January 15, 2025, Nadra will roll out a facial recognition verification facility accessible via the Pak-ID Mobile App and Nadra Registration Centers across the country. The initiative aims to reduce delays and provide seamless services to citizens. The conference also explored the potential of iris recognition technology as a future tool for identity verification. Participants discussed the benefits and potential challenges of implementing such advanced solutions. During the event, Nadra officials provided insights into the “National Registration and Biometric Policy Framework” and the “Digital Economy Enhancement Project (DEEP),” both of which aim to drive the country’s digital transformation and economic growth. With this technological advancement, Nadra aims to eliminate unnecessary delays in identity verification and improve service delivery for all citizens. The adoption of facial recognition marks a significant step towards inclusivity and modernization in Pakistan’s identity verification systems.Pet Grooming Market Emerging Trend, Industry Demand and Regional Analysis by 2031Why GTA 6's Second Trailer Hasn't Been Announced, According to Ex-Rockstar Dev - IGN Daily Fix
Update on plans to convert retail unit into 7-bed HMONadra to launch facial recognition system for elderly New initiative aims to streamline identity verification processes and ensure better access to essential services ISLAMABAD: The National Database and Registration Authority (Nadra) has announced the launch of a groundbreaking facial recognition system designed to assist elderly citizens, particularly pensioners, who face difficulties due to faded fingerprints. The new initiative aims to streamline identity verification processes and ensure better access to essential services. In a consultative conference held at Nadra headquarters, officials and representatives from various regulatory bodies convened to discuss advancements in biometric and identity verification systems. The conference served as a platform to address existing challenges and outline modernization efforts. Lt. Gen. Muhammad Munir Afsar, Chairman of Nadra, highlighted the issues faced by senior citizens, especially pensioners, during identity verification due to weakened fingerprints. He emphasized the importance of adopting modern technologies to cater to the needs of this vulnerable group. Starting January 15, 2025, Nadra will roll out a facial recognition verification facility accessible via the Pak-ID Mobile App and Nadra Registration Centers across the country. The initiative aims to reduce delays and provide seamless services to citizens. The conference also explored the potential of iris recognition technology as a future tool for identity verification. Participants discussed the benefits and potential challenges of implementing such advanced solutions. During the event, Nadra officials provided insights into the “National Registration and Biometric Policy Framework” and the “Digital Economy Enhancement Project (DEEP),” both of which aim to drive the country’s digital transformation and economic growth. With this technological advancement, Nadra aims to eliminate unnecessary delays in identity verification and improve service delivery for all citizens. The adoption of facial recognition marks a significant step towards inclusivity and modernization in Pakistan’s identity verification systems.
Mumbai: Businessman Raj Kundra, husband of actress Shilpa Shetty, is currently in Britain after skipping two summons in connection with an ongoing money laundering probe linked to a pornography case. According to sources, Kundra has requested an exemption to appear before the Enforcement Directorate (ED). The businessman travelled to Britain with his family to care for his ailing father and to make arrangements for his return to India. Kundra is expected back in India by the first week of January. His counsel, Prashant Patil, confirmed that Kundra’s presence in Britain was due to a family medical emergency, and he intended to cooperate with the ED upon his return.. Despite receiving two summons from the ED, Kundra has not appeared before the investigative agencies for over two weeks. Last month, Kundra sought permission from the Killa Court (Metropolitan Magistrate’s Court) in Mumbai to retrieve his passport and travel to Britain due to his father's critical illness. With the court’s approval, he went to Britain. However, a few days ago, again his father’s condition worsened, prompting Kundra and his family to decide to go to the UK in order to manage his treatment and care. Kundra recently vehemently denied the allegations of his involvement in the production of pornography. In a statement, he clarified that his role was limited to providing technological services to his brother-in-law’s UK-based company, Kenrin, which hosted the Hotshots app. He described the content as bold, aimed at an adult audience, He further claimed that the case against him was driven by business rivalry, which escalated into a personal attack. During his time in police custody, he revealed, “One night, someone approached me and asked, ‘Why did you get into a fight with him?’ That’s when I realised who was behind this conspiracy against me.” Kundra also revealed that he had written to the CBI, providing the names of individuals he believed were behind the conspiracy to damage his reputation. However, he refrained from publicly naming these individuals.
From Media Days to Game Days: How accurate were these media members' SEC Championship predictions?adidas AG ( OTCMKTS:ADDYY – Get Free Report ) was the target of a significant decrease in short interest during the month of December. As of December 15th, there was short interest totalling 7,500 shares, a decrease of 20.2% from the November 30th total of 9,400 shares. Based on an average trading volume of 76,600 shares, the short-interest ratio is currently 0.1 days. Analysts Set New Price Targets Several analysts recently weighed in on the stock. HSBC downgraded shares of adidas from a “buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. Barclays reaffirmed an “equal weight” rating on shares of adidas in a report on Monday, September 9th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy”. Get Our Latest Report on ADDYY adidas Stock Performance adidas ( OTCMKTS:ADDYY – Get Free Report ) last announced its earnings results on Tuesday, October 29th. The company reported $1.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.09 by $0.25. adidas had a net margin of 1.91% and a return on equity of 7.93%. The firm had revenue of $7.08 billion during the quarter, compared to analyst estimates of $7.01 billion. On average, equities research analysts predict that adidas will post 2.15 EPS for the current year. Institutional Inflows and Outflows A number of hedge funds have recently made changes to their positions in ADDYY. GAMMA Investing LLC lifted its position in adidas by 29.4% in the third quarter. GAMMA Investing LLC now owns 792 shares of the company’s stock worth $105,000 after purchasing an additional 180 shares during the period. Capital Square LLC acquired a new position in shares of adidas during the 2nd quarter valued at $1,616,000. Finally, Hantz Financial Services Inc. bought a new stake in shares of adidas in the 2nd quarter worth $4,809,000. adidas Company Profile ( Get Free Report ) adidas AG, together with its subsidiaries, designs, develops, produces, and markets athletic and sports lifestyle products in Europe, the Middle East, Africa, North America, Greater China, the Asia-Pacific, and Latin America. It offers footwear, apparel, and accessories and gear, such as bags and balls under the adidas brand; golf footwear and apparel under the adidas Golf brand; and outdoor footwear under the Five Ten brand. Read More Receive News & Ratings for adidas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for adidas and related companies with MarketBeat.com's FREE daily email newsletter .
ANDOVER, Mass. , Dec. 2, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the appointment of Mr. Gerardo Hernandez as the Company's Chief Financial Officer, effective December 2, 2024 . In this role, Mr. Hernandez joins the TransMedics executive leadership team, succeeding Mr. Stephen Gordon . To enable a smooth transition, Mr. Gordon will remain a non-executive employee of the Company until March 31, 2025 , before serving as a non-employee senior advisor to the Company focusing on national transplant stakeholder engagement until March 31, 2026 . TransMedics also updated its 2024 financial outlook. Dr. Waleed Hassanein , Mr. Gerardo Hernandez and Mr. Stephen Gordon will attend the upcoming Piper Sandler Conference on December 3, 2024 , the TransMedics Investor & Analyst Day on December 10, 2024 , as well as the J.P. Morgan Healthcare Conference in January 2025 . Mr. Hernandez is an accomplished finance leader with over 25 years of experience across the healthcare and consumer packaged goods (CPG) sectors. He most recently served as Vice President Finance, Head of Corporate Financial Planning and Analysis at Alnylam Pharmaceuticals, a biopharmaceutical company focused on RNAi therapeutics. In this role, Mr. Hernandez led a global team as the company scaled rapidly. Prior to his role at Alnylam, Mr. Hernandez spent nearly a decade at Shire, where he rose through the organization, eventually leading corporate FP&A. During his tenure, Shire was acquired by Takeda in a $62 billion transaction, after which he was instrumental in the integration effort. Mr. Hernandez began his career at Unilever where he held several finance roles of increasing responsibility before joining Shire in 2010. Mr. Hernandez holds a Bachelor of Science degree in Finance from the University of Wisconsin , La Crosse and an MBA in Strategy and Economics from Fundação Getulio Vargas , Sao Paulo, Brazil . "Stephen has been an exceptional partner to me as a member of the TransMedics leadership team for nearly a decade. During his tenure we transitioned the Company from a clinical stage organization to a high growth, publicly traded commercial business," said Waleed Hassanein , M.D., President and Chief Executive Officer. "On behalf of the entire management team and the Board, I want to thank Stephen for his countless contributions to our business that will have lasting benefits for the Company. I am grateful for Stephen's dedication and efforts to advance our corporate strategy while delivering considerable shareholder value, and I look forward to his continued partnership to affect a smooth transition as we start our next chapter at TransMedics." "I am delighted to welcome Gerardo to the TransMedics leadership team as our new Chief Financial Officer," added Dr. Hassanein. "His proven record over two decades of leadership across FP&A functions within high-growth, complex global organizations makes him an ideal addition to our team. I am looking forward to partnering with Gerardo as we continue to deliver significant long-term corporate growth and shareholder value." "I am thrilled to join TransMedics as Chief Financial Officer," said Mr. Hernandez. "I look forward to working with the entire leadership team to expand access to the Company's unparalleled products and services in the organ transplant field while enhancing operational efficiency and delivering lasting value to both our shareholders and the patients we serve." Dr. Hassanein concluded, "As we enter the final weeks of the fourth quarter, we are also updating our financial outlook for the full year 2024. Our updated guidance reflects our continued expectation for considerable year-over-year revenue growth. We look forward to providing additional context at our upcoming Investor & Analyst Day." 2024 Financial Outlook TransMedics now expects revenue for the full year 2024 to be in the range of $428 million to $432 million, which represents 77% to 79% growth compared to the Company's prior year revenue. Piper Sandler 36th Annual Healthcare Conference Members of the TransMedics management team will participate in a fireside chat at the upcoming Piper Sandler 36th Annual Healthcare Conference at the Lotte New York Palace. The fireside chat will take place on Tuesday, December 3, 2024 , at 4:00 p.m. Eastern Time . A live and archived webcast of the fireside chat will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com . The Company's standard investor presentation is also available through this link. TransMedics Investor & Analyst Day Details TransMedics will discuss the transition and updated financial outlook, as well as the Company's growth strategy, clinical pipeline, and operations, in greater detail at its Investor & Analyst Day in New York City on Tuesday, December 10, 2024 , at 10:00 a.m. Eastern Time . A live and archived webcast of presentations and Q&A sessions will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com . Please note management will only take questions from the live audience during the question-and-answer session following formal presentations. About TransMedics Group, Inc. TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts , the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure. Forward-Looking Statements This press release contains forward-looking statements with respect to, among other things, a leadership transition and our full-year guidance. For this purpose, all statements other than statements of historical facts are forward-looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "could," "target," "predict," "seek" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties. Our management cannot predict all risks, nor can we assess the impact of all factors or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in or implied by any forward-looking statements we may make. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated in or implied by the forward-looking statements. Some of the key factors that could cause actual results to differ include: our ability to maintain profitability on a sustained basis; our ability to attract, train and retain key personnel; our existing and any future indebtedness, including our ability to comply with affirmative and negative covenants under our credit agreement to which we will remain subject until maturity; the fluctuation of our financial results from quarter to quarter; our need to raise additional funding and our ability to obtain it on favorable terms, or at all; our ability to use net operating losses and research and development credit carryforwards; our dependence on the success of the Organ Care System or OCS; our ability to expand access to the OCS through our National OCS Program or NOP; our ability to scale our manufacturing and sterilization capabilities to meet increasing demand for our products; the rate and degree of market acceptance of the OCS; our ability to educate patients, surgeons, transplant centers and private and public payors on the benefits offered by the OCS; our ability to improve the OCS platform and develop the next generation of the OCS products; our dependence on a limited number of customers for a significant portion of our revenue; our ability to maintain regulatory approvals or clearances for our OCS products in the United States , the European Union, and other select jurisdictions worldwide; our ability to adequately respond to the Food and Drug Administration or FDA, or other competent authorities, follow-up inquiries in a timely manner; the performance of our third-party suppliers and manufacturers; our use of third parties to transport donor organs and medical personnel for our NOP and our ability to maintain and grow our logistics capabilities to support our NOP and reduce dependence on third party transportation, including by means of attracting, training and retaining pilots, and the acquisition, maintenance or replacement of fixed-wing aircraft for our aviation transportation services or other acquisitions, joint ventures or strategic investments; our ability to maintain Federal Aviation Administration or FAA or other regulatory licenses or approvals for our aircraft transportation services; price increases of the components of our products and maintenance, parts and fuel for our aircraft; the timing or results of post-approval studies and any clinical trials for the OCS; our manufacturing, sales, marketing and clinical support capabilities and strategy; attacks against our information technology infrastructure; the economic, political and other risks associated with our foreign operations; our ability to protect, defend, maintain and enforce our intellectual property rights relating to the OCS and avoid allegations that our products infringe, misappropriate or otherwise violate the intellectual property rights of third parties; the pricing of the OCS, as well as the reimbursement coverage for the OCS in the United States and internationally; regulatory developments in the United States, European Union and other jurisdictions; the extent and success of competing products or procedures that are or may become available; our ability to service our 1.50% convertible senior notes, due 2028; the impact of any product recalls or improper use of our products; our estimates regarding revenues, expenses and needs for additional financing; and other factors that may be described in our filings with the Securities and Exchange Commission (the "SEC"). Additional information will be made available in our annual and quarterly reports and other filings that we make with the SEC. The forward-looking statements in this press release speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and we are not able to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. Investor Contact: Brian Johnston Laine Morgan 332-895-3222 Investors@transmedics.com View original content to download multimedia: https://www.prnewswire.com/news-releases/transmedics-appoints-gerardo-hernandez-as-chief-financial-officer-and-provides-updated-2024-financial-outlook-302320060.html SOURCE TransMedics Group, Inc.None
Josh Allen’s creativity and Jameis Winston’s risk-taking produce statistical firsts in the NFLISLAMABAD, (UrduPoint / Pakistan Point News - 28th Dec, 2024) A delegation of Iqra University students visited Safe City under the Friends of internship program, where they were welcomed by Senior Superintendent of (SSP) Safe City Shoaib Khan on Saturday. A public relation officer told APP that the delegation visits the command and control center, the data unit, modern technology-equipped cameras, online and the operations center hall. They were fully briefed about the procedures and advantages of this project. Furthermore, the delegation was informed that Safe City is playing a significant role in various departments through modern techniques, including the Operations Center, Emergency Control Center, Data Unit, Dispatch Control Center, E-Challan System, online and the “Pucar-15” helpline. The delegation was also apprised of the functionality and benefits of the Safe City cameras in the city. The modern cameras of Safe City are playing a crucial role in ensuring the safety of the city, preventing crimes and safeguarding the lives and property of citizens. 42% of crimes are resolved through the Safe City Command and Control Center. Face recognition cameras have been installed at the entry and exit points of the city which are playing an important role in identifying suspicious elements, he added. The delegation acknowledged the modern technical system of the and its benefits. The delegation expressed special gratitude to and his team for this successful .4 Altcoins Making Waves to Invest in Now That Investors Shouldn’t MissNone
I'm A Celebrity viewers have spotted camp tension already as Dean McCullough took on another trial. The BBC Radio One presenter was up for his third trial of the series so far on Thursday night. He called ' I'm A Celebrity ...Get Me Out of Here!' on his first trial and failed to collect any stars on his second tasked when paired with social media star GK Barry. Dean hoped to secure a good meal in Thursday's trial , but it didn't go too well. He took on the Lethal Lab where he put his head in different boxes to try and undo the stars with his mouth. In typical I'm A Celebrity fashion, the boxes were filled with creepy crawlies. In the end, Dean collected four stars before declaring to quit the trial when fish guts filled the box. Dean appeared thrilled with his four stars as he rushed back to camp to let the others know. He was greeted with praise from his campmates, yet viewers noticed one celebrity didn't seem so impressed. McFly's Danny Jones failed to crack a smile or say anything to Dean as fans of the show admitted he was right to be annoyed. One viewer said: "Danny is absolutely not impressed." Another added: "Oop Danny does not look pleased." Someone else commented: "I think Danny is p***ed off which is completely understandable." A fourth wrote: "Danny McFly looks like he wants to kill him. Not buying his 4-star bulls**t at all." One fan echoed: "Danny didn’t look too impressed at failing at fishguts." Host Ant McPartlin had urged Dean to take on the challenge will full effort and not quit. Viewers at home issued a call as they declared a change must happen. They have urged others to stop voting for Dean to take on the Bushtucker Trials. One said: "I’m begging you all please leave dean and grace alone let someone else do the trials they have been through ENOUGH." Another added: "Can we agree as a collective to leave dean out of trials." Someone else commented: "Guys PLEASE stop voting dean in i feel so bad for him, don’t make my fav leave before he even gets the chance to win." A fourth wrote: "Idk who keeps voting for dean but it’s getting boring lads, leave him alone." Dean, 32, dramatically quit his Bushtucker trial on Tuesday night when he was only minutes into it. Speaking on I'm A Celebrity Unpacked, Ant and Dec said they were disappointed viewers didn’t get to see the full trial when Dean quit Sinister Sarcophagus on Tuesday night. Dec said: “We are genuinely disappointed because you are prepared to do the whole trial and you want to see the whole thing. There’s a lot of time gone into the trials so when it’s called early your like, ‘oh'. Follow Mirror Celebs on TikTok , Snapchat , Instagram , Twitter , Facebook , YouTube and Threads .